» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing


More information on quetiapine fumarate (Seroquel)

Letter Urging FDA to Reject Use of Quetiapine Fumarate (Seroquel) in Depression

April 9, 2009

Thomas Laughren, M.D.
Director, Division of Psychiatry Products
Food and Drug Administration / CDER
10903 New Hampshire Ave
WO Building 22, Room 4114
Silver Spring, MD 20993

Dear Dr. Laughren,

Yesterday, the Psychopharmacologic Drugs Advisory Committee met to discuss Seroquel XR for use in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), because of the FDA’s concern over the long-term toxicities of this drug. The committee voted unanimously that Seroquel is unsafe for use as first-line therapy in either MDD or GAD. The committee also voted that Seroquel is unsafe for use in “certain instances,” rejecting any role for use as second- or third-line monotherapy. However, the committee did vote that Seroquel is safe for use as adjunctive therapy in MDD only. We agree that Seroquel is unsafe for use as monotherapy for MDD or GAD, under any circumstance. If the FDA expands the use of Seroquel to include the indication of adjunctive therapy for MDD, we recommend stringent labeling, including a boxed warning clearly stating that Seroquel is contraindicated as monotherapy for MDD.

From over a decade of use in schizophrenia and bipolar disorder, it is known that Seroquel causes: (1) heavy sedation; (2) tardive dyskinesia – an irreversible, disabling movement disorder; and (3) metabolic derangements including weight gain, adverse effects on lipids, and hyperglycemia, all of which may confer cardiovascular risk. A large retrospective cohort study recently published in the New England Journal of Medicine also suggests that Seroquel and other atypical antipsychotics are associated with a large increase in risk of sudden cardiac death. Overall, Seroquel is less tolerable and far less safe than existing approved therapies for MDD or GAD.

Despite these adverse effects, rampant off-label and inappropriate prescribing of Seroquel and other atypical antipsychotics already occurs, especially in vulnerable populations. Elderly patients are increasingly placed on atypical antipsychotics to treat insomnia or delirium associated with dementia. There is little or no evidence of benefit in these settings, but the potential for harm is substantial, including heavy sedation and even an increased risk of death. In addition, recreational use of Seroquel is on the rise. Therefore, expanding the use of Seroquel to include common disorders such as MDD and GAD would open the floodgates for even greater inappropriate use, and increase the potential for diversion and abuse.

If there were no effective treatments for MDD and GAD, or if Seroquel was more effective than existing therapies, then perhaps its wide range of toxicities might be tolerated. However, this is not the case. Therefore, we strongly urge you to heed the recommendations of the advisory committee and not expand the label for Seroquel to include use as monotherapy in MDD or GAD. If Seroquel is approved for use as adjunctive therapy in MDD, a boxed warning that clearly prohibits its use as monotherapy is needed, given the potential for harm with this drug.


James Floyd, M.D.
Researcher, Public Citizen  

Sidney Wolfe, M.D.
Acting President, Public Citizen

cc: Robert Temple, M.D., Janet Woodcock, M.D., Joshua Sharfstein, M.D.

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.